Highlights
- Dr. Reddy’s consolidated net profit remained positive in the March 2026 quarter.
- Standalone results reported a net loss despite higher total income during the period.
- The stock traded near its 52-week high range during today's session.
Dr. Reddy's Laboratories Limited (NSE:DRREDDY) reported contrasting financial results for the quarter ended March 31, 2026. On a standalone basis, the company recorded total income of Rs 4,38,920 lakh. However, profit before tax stood at a loss of Rs 30,550 lakh, while net loss came in at Rs 21,940 lakh.
Earnings per share (EPS) was negative at Rs 2.63 for the quarter. Meanwhile, the consolidated financial results painted a different picture. Total income stood at Rs 8,02,180 lakh, while profit before tax reached Rs 19,510 lakh and net profit was reported at Rs 22,130 lakh. Consolidated EPS for the quarter was Rs 2.65.
Consolidated Results Remain In Positive Territory
The gap between standalone and consolidated performance highlights the contribution of subsidiaries and overseas operations to the broader business. While the standalone entity reported losses during the quarter, the consolidated business remained profitable. Consolidated earnings often provide a wider view of the company's operations across different geographies and business segments. The latest results indicate that profitability at the group level continued despite weakness in standalone operations.
Share Price Trades Near Annual Peak
Dr. Reddy’s shares were trading at Rs 1299.50 on June 23, 2026, reflecting a gain of Rs 11.20 or 0.68 percent from the previous close of Rs 1,290.70. The stock opened at Rs 1,297.20 and moved between an intraday low of Rs 1,294.90 and a high of Rs 1,329.50. The stock’s 52-week high stands at Rs 1,375.90, recorded on April 29, 2026, while the 52-week low is Rs 1,148.40, recorded on January 21, 2026. At current levels, the stock remains relatively close to its annual high and comfortably above its yearly low.
Valuation And Trading Metrics
Dr. Reddy’s Laboratories commands a market capitalisation of approximately Rs 1,08,665.57 crore, with a free-float market capitalisation of Rs 79,116.03 crore. The stock is a constituent of the Nifty 50 index and is trading at a price-to-earnings ratio of 26 times based on exchange data. Trading activity remained active during the session, with 17.70 lakh shares changing hands and generating traded value of around Rs 232.92 crore.
Return Performance Across Different Periods
The stock has delivered mixed returns over different investment horizons. Over the last week, the share price gained 1.66 percent. However, it declined 0.70 percent over the past month. On a year-to-date basis, the stock has risen 3.57 percent, outperforming the Nifty 50, which declined 8.05 percent during the same period. Over one year, the stock slipped 1.50 percent. Longer-term performance shows gains of 29.97 percent over three years and 22.48 percent over five years.
Key Risks To Watch
- Standalone operations reported a net loss in the latest quarter.
- Pharmaceutical pricing pressure may affect future earnings.
- Regulatory observations could impact manufacturing activities.
- Currency fluctuations may influence overseas revenue and profitability.
Today’s Share Performance
Dr. Reddy’s shares traded higher during the session, gaining 0.68 percent to Rs 1299.50 . The stock touched an intraday high of Rs 1,329.50 and a low of Rs 1,294.90. Trading volume stood at 17.70 lakh shares, while traded value was approximately Rs 232.92 crore. The company’s market capitalisation was Rs 1,08,665.57 crore and the stock traded at a P/E ratio of 26 times.
Source: TradingView
Summary
Dr. Reddy’s Laboratories (NSE:DRREDDY) reported a mixed set of March 2026 quarter results, with standalone operations posting a loss while consolidated operations remained profitable. The stock traded higher during today's session and stayed close to its 52-week high range. Going forward, investors may continue monitoring earnings trends, regulatory developments, pricing conditions and the performance of international operations.
FAQs
Q: What was Dr. Reddy’s consolidated net profit in the March 2026 quarter?
A: The company reported consolidated net profit of Rs 22,130 lakh for the quarter ended March 2026.
Q: Did Dr. Reddy’s standalone business report a profit?
A: No. The standalone business reported a net loss of Rs 21,940 lakh during the March 2026 quarter.
Q: How close is the stock to its 52-week high?
A: The stock is trading below its 52-week high of Rs 1,375.90 but remains near that level.